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Synaptic dysfunctionAlzheimer's disease (AD) is a neurodegenerative disorder characterized by hallmarks that include an accumula-
tion of amyloid-β peptide (Aβ), inﬂammation, oxidative stress and synaptic dysfunction,which lead to a decrease
in cognitive function. To date, the onset and progression of AD have been associatedwith pathologies such as hy-
pertension and diabetes. Hypertension, a disease with a high incidence worldwide, is characterized by a chronic
increase in blood pressure. Interestingly, this disease has a close relationship to the eating behavior of patients
because high Na+ intake is a signiﬁcant risk factor for hypertension. In fact, a decrease in Na+ consumption,
along with an increase in K+ intake, is a primary non-pharmacological approach to preventing hypertension.
In the present work, we examinedwhether an increase in K+ intake affects the expression of certain neuropath-
ological markers or the cognitive performance of a murine model of AD. We observed that an increase in K+ in-
take leads to a change in the aggregation pattern of the Aβ peptide, a partial decrease in some epitopes of tau
phosphorylation and improvement in the cognitive performance. The recovery in cognitive performance was
correlated with a signiﬁcant improvement in the generation of long-term potentiation. We also observed a de-
crease inmarkers related to inﬂammation and oxidative stress such as glial ﬁbrillary acidic protein (GFAP), inter-
leukin 6 (IL-6) and 4-hydroxynonenal (4-HNE). Together, our data support the idea that changes in diet, such as
an increase in K+ intake, may be important in the prevention of AD onset as a non-pharmacological therapy.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease is the most common cause of cognitive impair-
ment. This neurological disorder is characterized by the presence of
neuroﬁbrillary tangles, senile plaques (composed by the amyloid-β)
and synaptic dysfunction. Other features of AD include oxidative stress,
inﬂammation, Ca+2 imbalance, and disruption of signaling pathways
[1–3]. In recent years, several clinical studies have proposed what may
be an important factor in the progression of AD [4,5]. In fact, calorie re-
striction, theMediterraneandiet anddrinking redwine, rich in polyphe-
nols have been reported to attenuate AD deterioration of spatial
memory, delay the onset of dementia and reduce amyloid neuropathol-
ogy [5–7]. Epidemiological studies also suggest a relationship between
AD and systemic pathologies such as metabolic syndrome, obesity and
type II diabetes [5]. A common factor in these AD-related pathologiesh Center, Faculty of Biological
lameda 340, P.O. Box 114-D,
.is a chronic increase in blood pressure. Hypertension is deﬁned as per-
sistent systolic blood pressure ≥ 140 mm Hg and diastolic blood
pressure ≤ 90 mm Hg. Overall, approximately 20% of the population
worldwide has hypertension, and its incidence is increasing [8]. Hyper-
tension is considered a risk factor for several diseases, including hemor-
rhagic and ischemic stroke [9]. Furthermore, several studies have
reported that blood pressure is increased in AD patients, even decades
before the onset of the disease [5]. Furthermore, hypertension during
midlife has been associated with an increase in the number of senile
plaques in the neocortex and hippocampus and an augmentation of
neuroﬁbrillary tangles in the hippocampus. Therefore, prevention of hy-
pertension may attenuate the onset or progression of AD [5,10–12].
It has been reported that increase in K+ intake is beneﬁcial for blood
pressure and has no adverse effects [13–18]. In addition, several antihy-
pertensive agents have shown some prevention of cognitive decline,
diminishing the appearance of dementia related to AD in approximately
50% of study subjects [19]. In other reports, diuretics speciﬁcally,
potassium-sparing diuretics to treat high blood pressure had an effect
on dementia. These diuretics are associated with an important reduc-
tion of AD risk, and it is the antihypertensive treatment that has the
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the onset and progression of AD, we studied the effect of a diet enriched
in K+. In a typical recommended diet, dietary intake of K+ is at least 120
mmol/day (≈4.7 g/day); however, in theWestern diet, Na+ consump-
tion is high and K+ consumption is less than half of the recommended
amount [14,21,22]. This low K+ consumption has been associated
with diseases such as hypertension, stroke and cardiovascular diseases
[13,21,23].
In the present work, we used an animal model of AD: 4-month-old
transgenic APPswe/PSEN1 mice. The mice received 2% potassium in
their water for 8 weeks. Four-month-old animals were chosen because
at that age neither signiﬁcant cognitive loss nor brainAβ plaques are de-
tectable compared with 6-month-old mice (age at the end of treat-
ment), which exhibit high brain Aβ content and memory loss [24–26].
We observed that treatment with 2% potassium signiﬁcantly improved
cognitive performance,mainly in learning andmemory, suggesting a re-
covery in hippocampal activity. The improvement in cognitive perfor-
mance was correlated with an increase in LTP generation and a
decrease in inﬂammatorymarkers such us IL-6 andGFAP and the oxida-
tive stress marker 4-HNE. Together, these results suggest that an in-
crease in K+ intake results in the prevention of cognitive alterations
and oxidative stress in the early stages of AD in a mouse model.2. Methods
2.1. Animals and treatment
Male APPswe/PS1dE9 (4-month-old) and C57BL/6 (6-month-old)
mice were used in this study. APP/PS1 animals co-express a Swedish
(K594M/N595L) mutation of a chimeric mouse/human APP (Mo/
HuAPP695swe) together with the human exon-9-deleted variant of
PS1 (PS1-dE9); these mice secrete elevated amounts of human Aβ pep-
tide. This strain was obtained from The Jackson Laboratory (Bar Harbor,
ME, USA). The animals (wild type and APP) were separated into two
groups (17 animals by group); one group served as the control, the
other group was supplemented with 2% potassium chloride in the
drinkingwater [27]. The duration of the treatmentwas 8weeks, includ-
ing the behavioral tests. Mice were fed ad libitum. They were housed at
the Animal House Facility of the Facultad de Ciencias Biológicas,
Pontiﬁcia Universidad Católica de Chile. After treatment the mice were
used in the following order: 9 animals for the cognitive test and blood
analysis, 5 animals for electrophysiology experiments and 3 animals
for immunoblotting and immunoﬂuorescence analysis.2.2. Biochemical analysis
Blood was collected from the tail vein after 6 h of fasting and then
centrifuged at 2500 × g for 10 min at room temperature to obtain
serum samples. Glucose levels were measured using the hexoquinase/
G-6-PDHmethod in the Architect Analyzer (Abbott Laboratories, Abbott
Park, IL, USA), and insulin levels weremeasured via chemiluminescence
(Beckman Coulter); in both cases, the manufacturers' instructions were
followed. Triglyceride and cholesterol were assayed enzymatically in
the Architect c8000 (Abbott Laboratories, USA).2.3. Thioﬂavin-S (Th-S) staining
To detect amyloid formation, Th-S staining was developed using
brain slices mounted on gelatin-coated slides as previously described
[28,29]. Slices were dehydrated and rehydrated in xylene and ethanol
baths, followed by incubation in distilled water for 10 min. Next, slices
were immersed in Th-S solution (0.1% ThS in 70% ethanol) for 5 min
and then washed twice in 70% ethanol for 30 s and cover-slipped with
mounting medium in the dark.2.4. ELISA of Aβ42 and Aβ40 peptides
The brain sampleswere extracted on ice and immediately processed
as previously described [30]. Brieﬂy, tissues were homogenized in RIPA
buffer (10 mM Tris–Cl, pH 7.4, EDTA 5 mM, 1% NP-40, 1% sodium
deoxycholate, and 1% SDS) supplemented with a protease inhibitor
mixture (1 mM PMSF, 2 μg/mL aprotinin, 1 μg/mL pepstatin and
10 μg/mL benzamidine) and phosphatase inhibitors (25 mM NaF,
100 mM Na3VO4, 1 mM EDTA and 30 μM Na4P2O7) using a Potter ho-
mogenizer and then passed sequentially through different caliber syrin-
ges. Protein samples were centrifuged at 14,000 rpm at 4 °C twice for
15 min. Then, brain Aβ levels from 50 μL of the processed samples
were determined using Human Amyloid β40 and Amyloid β42 Brain
ELISA (Millipore), and the absorbance of each plate was read in a spec-
trophotometer (Metertech).
2.5. Immunoﬂuorescence
Immunoﬂuorescence in brain sliceswasperformed asdescribed pre-
viously [31,32]. Sliceswerewashed three times in ice-cold PBS and then
permeabilized for 30 min with 0.2% Triton X-100 in PBS. After several
rinses in ice-cold PBS, the samples were incubated in blocking solution
(0.2% bovine serumalbumin in PBS) for 1 h at room temperature follow-
ed by an overnight incubation at 4 °Cwith primary antibodies. After pri-
mary antibody incubation, the slices were extensively washed with PBS
and then incubated with Alexa-conjugated secondary antibodies (Mo-
lecular Probes, Carlsbad, USA) for 2 h at 37 °C. The primary antibodies
used were rabbit 4G8 and mouse anti-6E10 (Covance, Princeton, USA),
rabbit anti-IL-6 (Abcam, Cambridge, UK), rabbit nitrotyrosine (Abcam,
Cambridge, UK), rabbit 4-HNE (Abcam, Cambridge, UK), and rabbit
anti-GFAP (Dako, Denmark). The nuclear stain was performed by
treating the slices with Hoechst (Sigma-Aldrich, St. Louis, USA). The
slices were subsequently mounted on slides using mounting medium
and analyzed using a Zeiss LSM 5 Pascal confocal microscope. The im-
ages were analyzed using NIH Image J software.
2.6. Tricine-SDS PAGE
The brain sampleswere extracted on ice and immediately processed
as previously detailed [33]. Brieﬂy, tissues were homogenized in RIPA
buffer (10 mM Tris–Cl, pH 7.4, EDTA 5 mM, 1% NP-40, 1% sodium
deoxycholate, and 1% SDS) supplemented with a protease inhibitor
mixture (1 mM PMSF, 2 μg/mL aprotinin, 1 μg/mL pepstatin and
10 μg/mL benzamidine) and phosphatase inhibitors (25 mM NaF,
100 mM Na3VO4, 1 mM EDTA and 30 μM Na4P207) using a Potter ho-
mogenizer and then passed sequentially through different caliber syrin-
ges. Protein samples were centrifuged at 14,000 rpm at 4 °C twice for
15 min. Then, the proteins (100 μg) were separated by electrophoresis
performed in a Tris–Tricine buffer system [0.2 M Tris (pH 8.9) as an
anode buffer and 0.1 M Tris, 0.1M Tricine, 0.1% SDS (pH 8.25) as a cath-
ode buffer] and then transferred to a PVDF membrane. The transfers
were followed by incubation with the primary antibody 4G8 (Covance)
and anti-mouse IgG peroxidase conjugated antibody (Pierce, USA) and
developed using an ECL kit (Western Lightning Plus ECL, PerkinElmer).
2.7. Immunoblotting
The hippocampus was removed from each brain and homogenized
in RIPA buffer (50mM, Tris–Cl, pH 7.5, 150mMNaCl, 1%NP-40, 0.5% so-
dium deoxycholate, and 1% SDS) supplemented with a protease inhibi-
tor cocktail (Sigma-Aldrich P8340) and phosphatase inhibitors (50 mM
NaF, 1mMNa3VO4 and 30 μMNa4P207) using a Potter homogenizer and
then passed sequentially through different caliber syringes. Protein
samples were centrifuged at 14,000 rpm at 4 °C twice for 15 min. Pro-
tein concentration was determined using the Bicinchoninic Acid (BCA)
Protein Assay Kit (Pierce Biotechnology, Rockford, USA). Samples of
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polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a
polyvinylidene diﬂuoride (PVDF) membrane. Proteins were detected
by incubation with a primary antibody followed by a secondary anti-
goat peroxidase-conjugated antibody (Pierce) and developed using an
enhanced chemiluminescence (ECL) kit (Western Lightning Plus ECL,
PerkinElmer). The primary antibodies used were mouse anti-PHF-1
(Sigma-Aldrich); rabbit anti-tau (phospho-T231), rabbit anti-tau
(phosphor S235) and mouse anti-tau from Abcam; mouse anti-tau
AT8 (Thermo-Scientiﬁc) and rabbit anti-β-actin (Sigma-Aldrich),
rabbit anti-IL-6 (Abcam, Cambridge, UK) and rabbit anti-GFAP (Dako,
Denmark).
We thankDr. PeterDavies (Department of Pathology, Albert Einstein
College of Medicine, NY, USA) for his kind gift of the mouse anti-tau an-
tibody against epitope PHF-1.
2.8. Behavioral test
2.8.1. Classical model test
The Morris Water Maze (MWM) task was performed as we have
previously described [28,34]. Brieﬂy, mice were trained in a circular
pool 1.2 m in diameter (opaque water, 50 cm deep) and ﬁlled with
water at 19–21 °C. For training, a submerged 9 cm platform (1 cm
below the surface of water, invisible to the animal) was used with a
maximum trial duration of 60 s with 10 s on the platform at the end
of trials. Each animalwas trained to locate the platform; testingwas per-
formed with three trials per day, and swimming was monitoring using
an automatic tracking system (HVS Imagen, Hampton, UK). This system
was used tomeasure the latency time needed to reach the platform and
the time spent in each quadrant. After testing, the mouse was removed
from the maze, dried and returned to its cage.
2.8.2. Memory ﬂexibility test
This test was performed as previously described [28,34]. The condi-
tions of the pool were the same as described for theMWM. Each animal
was trained for one pseudo-random location of the platform per day, for
5 days, with a new platform location each day. Training was conducted
for up to 10 trials per day, until the criterion of 3 successive trialswith an
escape latency of b20 s was achieved.When testingwas completed, the
mouse was removed from the maze, dried and returned to its cage. An-
imals were tested for the next location on the following day. Data were
collected using a video tracking system (HVS Imagen).
2.8.3. Novel Object Recognition (NOR) task
This task takes advantage of a rodent's spontaneous preference to
explore novel objects relative to familiar objects. This test is the bench-
mark test of recognition memory in the rodent and is dependent on the
integrity of the hippocampus. The NOR paradigm was performed fol-
lowing the protocol described previously [35,36]. Brieﬂy, micewere ha-
bituated to the experimental room in the experimental cages for 3
consecutive days, 30min each day and for 1 h on the testing day. Testing
took place in 25 cm × 25 cm opaque walled cages. For object familiari-
zation, mice were allowed to explore their cage in the presence of two
identical objects. Following this, animals were returned to their home
cages for 1 h, followed by a 2.5 min exposure to a novel object. Mice
had no observed baseline preference for the different objects. An object
preference indexwas determined by calculating the time spent near the
novel object divided by the cumulative time spent with both familiar
and novel objects. Cages were routinely cleaned with ethanol following
testing/habituating of mice.
2.8.4. Large open-ﬁeld (LOF) test
A 120 × 120 cm transparent Plexiglas platform with 35-cm-high
transparent walls was used to study locomotor and stress behavior in
our mouse model because the use of a large platform is more effective
than that of a small one for the study of behavior. The open ﬁeld,which measured 40 × 40 cm, was deﬁned as the “center” area of the
ﬁeld. Data were collected using an automatic tracking system (HVS
Imagen, Hampton, UK). Each mouse was placed alone in the center of
the open ﬁeld, and its behavior was tracked for a 20 min session. At
the end of the session, themousewas returned to its home cage. The pa-
rameters measured included total time moving, time in the center and
corner, and number of times the mouse crossed the center area of the
platform [37].
2.9. Electrophysiological recording
Hippocampal slices were prepared using standard procedures as
previously described [36]. Brieﬂy, transverse slices (350 μm) of the dor-
sal hippocampus were cut under cold artiﬁcial cerebrospinal ﬂuid and
incubated in ACSF for 1 h at room temperature. In all experiments
10 μM picrotoxin (PTX) was included. Basal excitatory synaptic trans-
mission was measured using an input/output curve protocol [38],
which consisted of eight stimuli that ranged from 200 to 900 μA (with
a 10-s interval between stimuli). LTP was generated using TBS, which
consisted of 5 trains of the stimulus using an inter-train interval of 20 s.
2.10. Real-time PCR (QRT-PCR)
After Wnt3a treatment, we obtained RNA from the neuronal cul-
tures. The RNA samples were treated how we described previously
[39]. We used the following set of primers: cyclophilin: sense 5′-TGGA
GATGAATCTGTAGGAGGAG-3′ and antisense 5′-TACCACATCCATGCCC
TCTAGAA-3′; GFAP sense 5′-ACTCAATACGAGGCAGTGGC-3′ and anti-
sense 5′-CTCTAGGGACTCGTTCGTGC-3′ and IL-6 sense 5′-CACTTCACAA
GTCGGAGGCT-3′ and antisense 5′-CTGCAAGTGCATCATCGTTGT-3′.
2.11. Statistical analysis
The results are expressed as the mean ± standard error. Data were
analyzed by one-way or two-way analysis of variance (ANOVA) follow-
ed by Bonferroni's post hoc test; *p ≤ 0.05 and **p ≤ 0.01 were consid-
ered signiﬁcant. Statistical analyses were performed using Prism
software (GraphPad, La Jolla, CA).
3. Results
3.1. Changes in Aβ neuropathology in APP/PS1 mice supplemented with di-
etary potassium
To evaluate the general state of animals after the treatment,wemea-
sured several blood parameters, including glucose, insulin, cholesterol
and triglycerides. We observed no signiﬁcant differences between the
treated and control group (Table 1). To determine whether the treat-
ments affected the Aβ burden, we carried out the thioﬂavin (Th-S)
staining in the cortex and hippocampus in the brains of APP/PS1 mice
treated or not with K+ (Fig. 1A, a–d). In the hippocampus, we did not
observe changes in the Aβ burden in either the control or the treated
group (Fig. 1A, e). However, in the cortex, we observed a 2.5-fold in-
crease in the percentage of senile plaques in the treated group (Fig.
1A, f). Interestingly, we observed a signiﬁcant change in the size of the
senile plaques; treatment with potassium increased plaques smaller
than 100 μm2 (39.2 ± 0.4%) and decreased senile plaques larger than
200 μm2 (70 ± 3%) (Fig. 1A, g). Using ELISA detection, we measured
the concentrations of Aβ1-42 and Aβ1-40 in the hippocampus and ob-
served a signiﬁcant decrease in the concentration of Aβ1-42 from
450± 45 pg/ml in the control condition to 300± 25 pg/ml in the treat-
ed group (Fig. 1B, a). We did not observe differences in Aβ1-40 levels or
in the Aβ1–42/Aβ1–40 ratio (Fig. 1B, b and c).
We also studied the expression of Aβ deposits, using the 6E10 anti-
body, which is reactive to amino acid residues 1–16 of β-amyloid [24,
40]. We did not observe changes in the levels of expression after the
Table 1
Blood values after the treatment with 2% K+.
Glucose
(mg/dL)
Insulin
(μIU/mL)
Cholesterol
(mg/dL)
Triglycerides
(mg/dL)
Control 92 ± 12 1.3 ± 0.3 122 ± 11 100 ± 12
2% K+ 105 ± 10 0.9 ± 0.1 120 ± 11 109 ± 10
The values are expressed as the means ± SEM of n: 9 animals per group. *p b 0.05 and
**p b 0.01 based on ANOVA (one-way) followed by Bonferroni post hoc analysis.
Fig. 1. Changes inAβ neuropathology inAPP/PS1mice treatedwith KCl. Brain slices fromAPP/PS
cortex and hippocampus. Th-S-positive area fraction for hippocampus and cortex in control and
KCl-treated APP/PS1mice in cortex (e) and hippocampus (f), and cumulative frequency of amyl
pal lysates of both control and KCl-treated mice by a sandwich-type ELISA assay (B, a). Quantiﬁ
wich-type ELISA assay (B, b). Aβ ratio (Aβ42/Aβ40) was calculated for both conditions (B, c). Da
hoc Bonferroni's test. Asterisks indicate statistical signiﬁcance of the observed differences (*p b
2633P. Cisternas et al. / Biochimica et Biophysica Acta 1852 (2015) 2630–2644treatmentwith K+ in hippocampus. However, the staining of plaques in
animals supplemented with 2% potassium seemed to be less deﬁned
and more diffuse (Fig. 2A, a–b). We also observed that the immunoﬂu-
orescencewas present in amajority of the area in comparisonwith con-
trol transgenic animals, where plaques appear more compact and
deﬁned (Fig. 2A, c and d). To go further in the study of Aβ plaque confor-
mation, we used a second antibody, 4G8, which is speciﬁc for amino
acid residues 17–24 of the Aβ peptide [41,42], and observed a result
similar to that using the 6E10 antibody with diffuse plaques in both1 controlmice and treatedwith 2%KClwere stainedwith Th-S to detect amyloid plaques in
treated conditions (A, a–d). Cumulative frequency plot of amyloid plaque for control and
oid plaque size in both conditions (g). Quantiﬁcation of Aβ1–42 levels present in hippocam-
cation of Aβ1–40 levels present in hippocampus lysate in both conditions through a sand-
ta are means± S.E.M. Signiﬁcant differences were calculated by ANOVA, followed by post
0.05); n = 3 per group. Scale bar: 100 μm.
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showed the similar patter than the result obtained with 6E10 antibody
(Fig. 2B, c and d) Using Western blot for 4G8, we observed a decrease
in the plaque size. Further studies are required to resolve this issue
(Fig. 2B, e and f).
Phosphorylation of tau, particularly the appearance of the epitope
PHF-1 (phosphorylated Ser-396 and Ser-404) and AT8, were analyzed
in the hippocampus. We observed that treatment with 2% potassium
decreased the expression of tau-PHF1 and tau-AT8 by 25% and 15%,
respectively (Fig. 3a–c). However, we did not observe differences in
other epitopes of tau, including tau-T231, tau-S235 and total tau
[43–45] (Fig. 3d–f).Fig. 2. Representative immunoﬂuorescence for Aβ inAPP/PS1mice treatedwith KCl. Localization
PS1mice and KCl-treatedmice (A, a and b). Quantiﬁcation of the expression of 6E10 by area (μm
ing in the cortex and hippocampus of control APP/PS1 mice and KCl-treatedmice (B, a and b). Q
Tricine-SDS PAGE analysis of 4G8 in brain lysate of both conditions and the corresponding quan
calculated by ANOVA, followed by post hoc Bonferroni's test. Asterisks indicate statistical signiThese results suggest that a diet supplemented with potassiummay
affect the processing or clearance of Aβ deposits, promoting the diffu-
sion of Aβ plaques, a decrease in plaque size and a decrease in some epi-
topes of Tau phosphorylation.
3.2. The increase in potassium intake triggers improvement of cognitive
performance
We studied the general condition of both groups and did not observe
changes in blood parameters such as glucose, cholesterol and insulin. To
study the general behavior of the mice, we performed the open-ﬁeld
test and did not ﬁnd signiﬁcant differences between the control andof Aβdeposits using 6E10 immunostaining in the cortex andhippocampusof control APP/
2) in the cortex (A, c) and hippocampus (d). Aβ deposit detectionwith 4G8 immunostain-
uantiﬁcation of 4G8 expression by area (μm2) in the cortex and hippocampus (B, c and d).
tiﬁcation of Aβ17–42 levels (B, e and f). Data aremeans± S.E.M. Signiﬁcant differenceswere
ﬁcance of the observed differences (*p b 0.05); n = 3 per group. Scale bar: 50 μm.
Fig. 3. Tau expression in APP/PS1mice treatedwith KCl.Western blot analysis of several epitopes of tau (S235, AT8, PHF1, T231) and total tau in the hippocampus of APP/PS1 control mice
and KCl-treatedmice (a). Quantiﬁcation of the levels of each epitope in both conditions: PHF1 (b), AT8 (c), total tau (d), T231 (e), S235 (f). Data aremeans± S.E.M. Signiﬁcant differences
were calculated by ANOVA, followed by post hoc Bonferroni's test. Asterisks indicate statistical signiﬁcance of the observed differences (*p b 0.05); n = 3 per group.
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center of the cages. Furthermore, neither group showed differences in
comparisonwith thewild-typemice, suggesting normal general behav-
ior (Fig. 4a and b). Then,we performed theMWMand observed a signif-
icant change in the latency time during the consolidation phase in the
last 3 days of the experiment. The wild-type animals took 23.5 ± 4.3 s
to ﬁnd the platform, whereas the control and treated groups took
43.5 ± 6.1 s and 30.3 ± 2.6 s, respectively (Fig. 4c). We did not observe
changes in the speed of movement between the control and the treated
group (Fig. 4d). Finally, we observed that after the removal of the plat-
form, the treated group spent more time in the quadrant where the
platformwas previously located, therefore, the potassium intake helped
to recover this cognitive function; however, it was insufﬁcient to match
the wild-type performance (Fig. 4e).
Therefore, we evaluated mice performance using a modiﬁed spatial
memory paradigm associated with episodic memory (memory ﬂexibil-
ity), a technique that ismore sensitive to hippocampal dysfunction [46].
We observed that after 5 days, the treated group presented a signiﬁcant
difference from the control group, with the treated group taking 8 trials
to reach the criteria and the control group taking more trials (14)
(Fig. 4f). Finally, we studied the effect of potassium intake on the NORtest, and the results showed an improvement in the performance of
the potassium-treated group in comparison with the control group
(Fig. 4g). These results showed that an increase in potassium intake
clearly leads to an improvement in the cognitive performance of ADmice.
3.3. The increase of K+ intake improves hippocampal synaptic plasticity
We then examined the effects of a diet containing potassium supple-
ment on synaptic plasticity to elucidate the potentialmechanismunder-
lying our behavioral results. Synaptic integrity was assessed using
electrophysiological recordings for input–output analysis [36,47]. The
ﬁeld excitatory postsynaptic potential (fEPSP) showed improvement
in the treated group in comparison with the control group (Fig. 5a). Ad-
ditionally, the ﬁber volley, an indicator of axonal excitability, recovered
in amplitude (Fig. 5b and c), which indicates an improvement in
synaptic transmission at the presynaptic level. Synaptic plasticity was
assessed by measuring LTP, which reﬂects persistent changes both in
synaptic connectivity and in the underlying learning andmemory func-
tions. Experimentally, a set of protocols for theta burst stimulation and
low-frequency stimulation (LFS) were used to induce LTP and LTD, re-
spectively. It was not possible to induce robust LTP in the control
Fig. 4. Behavioral test in APP/PS1 mice treated with KCl. Behavior performance in C57bl6 control mice and APP/PS1 control or treated with 2% of KCl in the drinking water for 8 weeks. In
the open-ﬁeld test, exploring behavior was measured. After treatment, each experimental group was placed in the open-ﬁeld apparatus, and their (a) moving time and (b) number of
crossing lines were measured. In the MWMwemeasured (c) escape latency (time required to reach the hidden platform), (d) swimming speed and (e) the time spent in each quadrant
in the absence of the platform. (f) Behavioral performance in the memory ﬂexibility test was analyzed by assessing the number of trials needed to meet the criteria. (g) Analysis of the
recognition index (time spent exploring the novel object/time spent exploring the novel and the old objects) in thememoryﬂexibility test. Data aremeans± S.E.M. Signiﬁcant differences
were calculated by ANOVA, followed by post hoc Bonferroni's test. Asterisks indicate signiﬁcant observed differences (*p b 0.05); n = 9 per group.
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maximum of 1.99 ± 0.22 mV in the treated group (Fig. 5d). Further-
more, the induction and maintenance of LTP in the control group
persisted for at least 60min of recording, 1.07 ± 0.11 mV in the control
group and 1.67 ± 0.14 mV in the treated group (Fig. 5e). These results
suggest that the increase in potassium intake leads to a recovery of hip-
pocampal synaptic transmission and plasticity.
3.4. Increased potassium intake attenuates the expression of the oxidative
stress marker 4-HNE
Oxidative stress is triggered by an imbalance between oxidants and
antioxidants in favor of the formation of oxidized compounds and re-
sults in damage to membranes, proteins and DNA [48]. Extensive early
work demonstrated that oxidative stress plays a role in the onset of
AD [49–52]. Tissue oxidative stress markers include lipid peroxidation,
protein oxidation, DNA oxidation, and structurally and functionally
damaged mitochondria [53,54]. We analyzed a marker of lipidperoxidation, 4-HNE. In the control group, we observed strong expres-
sion of this marker, in both the cortex (Fig. 6A, a–d) and in the hippo-
campus (Fig. 6A, e–h). The expression of 4-HNE decreased in the
treated group by approximately 30% in the hippocampus and 50% in
the cortex (Fig. 6A, i); the immunoﬂuorescence signal was measured
relative to the control group in both regions. Our data suggest that the
increased potassium intake partially prevented the oxidative stress
present in the APPswe/PS-1 transgenic mouse AD model.
Also, we study the expression of nitrotyrosine other marker of oxi-
dative stress product of tyrosine nitrationmediated by reactive nitrogen
species such as peroxynitrite anion and nitrogen dioxide [55]. We ob-
served a decrease in the mark only in the hippocampus and not signiﬁ-
cant difference in cortex of both groups (Fig. 6B, a–e).
3.5. Increased potassium intake decreases glial activation
Increased astrogliosis is an undisputed feature of AD brains with in-
creased Aβ loads [56,57]. Brain sections obtained from the control
Fig. 5. Potassium effects in hippocampus excitability. Field recordings of hippocampal slices from APP/PS1 control mice andmice treated with KCl. (a–c) Synaptic integrity was evaluated
via input–output analysis of the electrophysiological recordings. (d–e) LTP recording, plot of fEPSP amplitude versus time in hippocampal slices of both groups. The values are expressed as
means ± SEM of 5 animals per group. *p b 0.05 based on ANOVA (one-way), followed by Bonferroni post hoc analysis.
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a–d) and hippocampus (Fig. 7A, e–h), while the treated group showed
a decrease in the expression of the oxidative marker, mainly in hippo-
campus (Fig. 7, i). To support these results we performed QRT-PCR
against the mRNA of GFAP and we observed a signiﬁcant decrease
(70%) in the levels ofmRNA only in hippocampus (Fig. 7B). Also we cor-
related the result from QRT-PCR and immunoﬂuorescence with West-
ern blot and with this methodology we only observed a decrease in
the levels of GFAP in the hippocampus, without changes at cortex levels
(Fig. 7C, a and b). The decrease in the number of GFAP levels could be
correlated with a decrease in brain inﬂammation mainly in
hippocampus.
3.6. Increased potassium intake treatment decreases the expression of IL-6
inﬂammation marker
Neuroinﬂammation is one of the cellular and neurochemical pro-
cesses that may underlie neurodegeneration [58–60]. As a prototypical
cytokine with roles in the control of inﬂammation, IL-6 is altered in
many central nervous system (CNS) diseases. IL-6 is overexpressed in
the brains of AD patients and increased around amyloid plaques and
in the cerebrospinal ﬂuid (CSF) [61,62]. Wemeasured IL-6 in the cortex(Fig. 8A, a–d) and in the hippocampus (Fig. 8A, e–h) of both the treated
and control groups. A trend for decreased IL-6 staining was observed in
the hippocampus of K+-treatedmice, but this difference was not signif-
icant (Fig. 8A, e–h). Treatment with 2% K+ decreased the expression of
IL-6 primarily in the cortex, while in the transgenic control we observed
strong expression of this cytokine (Fig. 8A, a–d). The quantiﬁcation of IL-
6 signal showed a decrease in the cortex to nearly 58% (Fig. 8A, i). Using
QRT-PCRwe observed a decrease in themRNA levels of IL-6 both cortex
and hippocampus (Fig. 8B). Finally using Western blot we observed a
decrease in the proteins of IL-6 only in cortex (Fig. 8C, a and b). These
results suggest that the increase in the intake of K+ stimulate a partial
delay in the progress of inﬂammation.
4. Discussion
In the presentwork, we showed that an increase in potassium intake
in early stages of AD triggers a delay in the expression of somemarkers
of AD in amousemodel. The increased intake of K+ led to a reduction in
the level of Aβ1-42. Additionally, diffusion of the smallest plaques and
plaques increased. Furthermore, the diet decreased the tau of important
antigenic sites, including PHF-1, associated with the onset of AD. The
diet supplemented with K+ stimulated and improved cognitive
Fig. 6. 4-HNE detection in the brains of APP/PS1 mice. Representative immunoﬂuorescence for 4-HNE in APP/PS1 control mice and mice treated with KCl. 4-HNE, green; nuclear stain
Hoechst, blue. 4-HNE in hippocampus and cortex (A, a, b, e and f) of control mice and hippocampus and cortex of mice treated with KCl. (A, c, d, g and h) Quantiﬁcation of the immuno-
ﬂuorescence signal normalized to that of the control transgenic animals (A, i). Immunoﬂuorescence for nitrotyrosine in cortex and hippocampus (B, a-d). Quantiﬁcation of signal (B, e).
Data are means ± S.E.M. Signiﬁcant differences were calculated by ANOVA, followed by post hoc Bonferroni's test. Asterisks indicate signiﬁcant observed differences (*p b 0.05; ***p b
0.001); n = 3. Scale bar: 100 μm.
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covery was correlated with recuperation in neuronal plasticity at the
level of LTP, the neurophysiological correlate of memory. Additionally,
the diet enriched in K+ induced a decrease in several histopathological
ADmarkers, includingGFAP, IL-6 and 4-HNE. Together, our data suggestthat a diet rich in K+ could serve as a preventive factor against the onset
or early progression of AD (Fig. 9).
AD is the most common form of dementia associated with age, af-
fecting approximately 36 million people worldwide. It is estimated
that by 2050 the number of cases will rise to 110 million [5,63,64].
Fig. 7.GFAP detection in the brains of APP/PS1mice. Representative immunoﬂuorescence for GFAP in APP/PS1 control mice andmice treatedwith KCl. GFAP, green; nuclear stain Hoechst,
blue. GFAP in the hippocampus (A, e and f) and cortex (A, a and b) of control mice and hippocampus (A, g and h) and the cortex (A, c and d) of mice treatedwith KCl. Quantiﬁcation of the
immunoﬂuorescence signal normalized to that of the control conditions (A, i). QRT-PCR formRNA levels ofGFAP (B).Western blot against GFAPand quantiﬁcation (C, a and b). Data are the
means±S.E.M. Signiﬁcant differenceswere calculated byANOVA, followed by post hoc Bonferroni's test. Asterisks indicate signiﬁcant observed differences (*pb 0.05; ***pb 0.001); n=3.
Scale bar: 100 μm.
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the presence of extracellular Aβ aggregates, and by intracellular clusters
of hyper-phosphorylated tau protein, i.e., the neuroﬁbrillary tangles
(NFTs). However, there are other markers of onset and progression of
AD, such as activation of glial cells, metabolic disorders, oxidative stress
and inﬂammation. Together, these forms of cellular dysfunction lead
to the clinical manifestation of the disease [1,65–67]. Clinically, AD ischaracterized by a progressive loss of cognitive abilities, including
memory and learning. The cognitive failure has been correlated
with the loss of synapses and dendritic structures; both processes
are related to the described neurodegeneration observed in AD [2,
68]. Although no cure exists for AD, and the molecular mechanisms
that trigger the disease are not fully understood, several studies
have suggested diverse mechanisms to explain the onset of AD. In
Fig. 8. IL-6 detection in the brains of APP/PS1mice. Representative immunoﬂuorescence for IL-6 inAPP/PS1 controlmice andmice treatedwith KCl. IL-6, green; nuclear stainHoechst, blue.
IL-6 in the hippocampus (A, e and f) and cortex (A, a and b) of control mice and the hippocampus (A, g and h) and cortex (A, c and d) of mice treated with KCl. Quantiﬁcation of the im-
munoﬂuorescence signal normalized to that under control conditions (A, i). QRT-PCR for mRNA levels of IL-6 (B). Western blot against IL-6 and quantiﬁcation (C, a and b). Data are the
means ± S.E.M. Signiﬁcant differences were calculated by ANOVA, followed by post hoc Bonferroni's test. Asterisks indicate signiﬁcant observed differences (*p b 0.05; ***p b 0.001);
n = 3. Scale bar: 100 μm.
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could be an important factor in the onset and progression of AD [5].
In fact, some epidemiological studies have suggested a relationship
betweenmetabolic syndrome and AD that links unhealthy nutrition-
al behavior and its associated diseases, such as obesity, hypertension
and diabetes mellitus type 2, with the onset of dementia syndromes,
including AD [69,70].Hypertension has a direct correlation with diet; elevated intake of
Na+ stimulates an increase in blood pressure. In the Western diet,
meals have high levels of Na+ and very low levels of K+, and it has
been suggested that an increase in K+ intake could be an efﬁcient,
non-pharmacological strategy to prevent hypertension and associated
diseases [13,15,17,23]. In fact, epidemiological studies have shown
that hypertension leads to dementia and cognitive decline. However,
Fig. 9. Summary of the effects of K+ intake on ADmarkers. The intake of 2% began at an age without the presence of ADmarkers. After 8 weeks, the transgenic mice without K+ supple-
mentation showed an increase in the numbers of Aβ, phosphorylation of tau. Additionally,we observed a decrease in cognitive performance and in neuronal plasticity. Finally,we observed
an increase in the expression of the inﬂammation and oxidative stress markers IL-6, GFAP and 4-HNE. All the mentioned histopathological ADmarkers decreased in the transgenic mice
supplemented with 2% K+, suggesting a delay in the onset of AD. These results suggest that changes in diet could help delay the onset of AD.
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planation of the interaction between hypertension andAD is that chron-
ic hypertension leads to several pathological alterations, including
effects on brain protein processing. In fact, in patients with hyperten-
sion, increased numbers of NFTs and amyloid plaques in post-mortem
brains have been described, indicating a direct link between hyperten-
sion and AD [75,76].
In our APPswe/PS-1 transgenicmodel, AD pathology is established at
approximately 6 months of age. We therefore treated mice in a pre-AD
state by starting the treatment at 4 months of age, with the intent of
learning whether the diet rich in K+ could prevent the onset of the
AD. In relation to the main brain marker of AD, Aβ aggregates, we ob-
served an increase in both the number of small senile plaques and
plaque diffusion. The size of plaques and the grade of diffusion could
be related to APP processing and consequently to the generation of Aβ
aggregates. In ourmodelwe studied the size of Aβ aggregates using sev-
eral approaches described in literature including antibodies 4G8 and
6E10 and the thioﬂavin stain, with all this methodologies we observed
a similar result, supporting our observation [40,42,77–79]. Therefore,
the increase in small plaques triggered by 2% K+ intake might suggest
increases in APP processing to promote the elimination of the Aβ pep-
tide [80,81]. Additionally, we observed a decrease in the concentration
of Aβ1-42, an important aspect considering that Aβ1-42 is critical in the
aggregation of the Aβ peptide. Aggregation alongwith the resulting for-
mation of senile plaques, highlight the importance of Aβ1-42 levels as an
important biomarker of AD progression. In fact, the concentration of
Aβ1-42 in the cerebral spinal ﬂuid (CSF) is a biomarker of both AD pro-
gression and Aβmetabolism in brain, primarily in the CSF [82,83].
The increase in K+ intake also led to a decrease in two of themarkers
for tau hyperphosphorylation, an important ﬁnding given that the pro-
gression of AD is affected by the presence of phosphorylated tau [43,44].
The major clinical manifestation of AD is the loss of cognitive capac-
ities. In our model, we evaluated whether the increase in K+ intakeaffected this response in the early stages of AD. First, we used the
MWM test to study spatial learning and memory, processes that both
depend, in part, on hippocampal structure [84,85]. In the transgenic
mice, we observed a signiﬁcant increase in latency time, whichwas par-
tially recovered in the group treated with K+. Interestingly, this recov-
ery occurred in the last three days of experiments, which corresponds
to processes associatedwith the establishment ofmemory in the hippo-
campus and other brain regions [86]. To further evaluate the implica-
tions of hippocampal activity, we performed the NOR test, which is
used to evaluate cognition, particularly recognitionmemory, in rodents.
This test is based on the spontaneous tendency of rodents to spend
more time exploring a novel object than a familiar one. The choice to ex-
plore the novel object reﬂects the use of learning and recognitionmem-
ory [87]. Using this test, we observed an increase in the recognition
index in the animals treated with K+, a result that conﬁrms a recovery
of cognitive processes and also supports the data obtained in the
MWM, which together suggest a recovery of hippocampal activity. To
study hippocampal function and neuronal plasticity, we performed
electrophysiological studies and observed that the control transgenic
mice could not generate efﬁcient LTP and also showed decreased poten-
tiation activity, as we observed previously [28,30,36]. By contrast, the
group treated with K+ displayed partial recovery of LTP generation
and an increase in hippocampus excitability. Together, these ﬁndings
suggest that K+ intake induces partial recovery in the brain function
of AD model mice, primarily in processes related to learning, memory
and neuronal plasticity. Finally, we studied whether the intake of K+ af-
fects the expression of othermarkers of AD progression, such as glial ac-
tivation, oxidative stress and inﬂammation.
Glial activation and inﬂammatory processes have been described in
several neurodegenerative diseases, including AD. Both processes have
also been correlated with oxidative stress. In fact, the damage induced
by oxidative stress in the hippocampus has been suggested as being crit-
ical to the failure of cognitive performance in ADpatients [88–91]. In our
2642 P. Cisternas et al. / Biochimica et Biophysica Acta 1852 (2015) 2630–2644model, we observed that the intake of K+ decreased expression of the
oxidative stress marker 4-HNE, a marker of lipid peroxidation [92].
The decrease in the 4-HNE signal was signiﬁcant in all hippocampus re-
gions as well as in the cortex. In both regions, an increase in the expres-
sion of 4-HNE during the progression of AD has been described [93–96].
We also observed a decrease in glial activation in the group treated
with K+. Activation of astrocytes has been described in several models
of neurodegenerative disease and has been postulated to represent a
common alteration in AD in response to neuronal damage [97,98].
Neuronal damage in AD induced by Aβ aggregates (amyloid ﬁbrils and
Aβ oligomers) could be an important trigger for the activation of glial
cells. The activation of glial cells is a well-recognized characteristic of
an inﬂammatory response in the progression to brain damage
[98–102]. The reduction in the number of cells positive for GFAP was
correlated with a decrease in the inﬂammatory marker IL-6. The activa-
tion of glial cells induced the production of IL-6 by blood cells, including
T-cells and monocytes. In brain tissue, IL-6 stimulates several processes
related to protection against brain injury, including tissue remodeling,
reduction of oxidative stress and inhibition of apoptosis induced by an
increase in intracellular Ca+2 [103–105]. However, themolecularmech-
anisms responsible for the effects of IL-6 remain unclear.
Together, all the data suggest that an increase in the intake of K+
could help prevent pathologies such as hypertension, which could pos-
sibly prevent or retard the onset of cognitive-related diseases such as
AD (Fig. 9). The positive effects described for the K+ diet could be an in-
teresting non-pharmacological therapy at least to some extent, the inci-
dence of cognitive decline and the progression of AD.
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